Company Comparison
BioNTech vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | BioNTech | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Mainz that develops immunotherapies and vaccines, particularly | South San Francisco, California |
| Founded | — | 2006 |
| Status | Active | Active |
| Last Funding Stage | — | — |
| Total Funding | — | — |
| Valuation | — | — |
What They Build
BioNTech
BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Sector Overlap
Both BioNTech and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.